QUICK SEARCH:   [advanced]
Author:
Keyword(s):
Year:  Vol:  Page: 

   

 

Health Affairs, 23, no. 5 (2004): 210-216
doi: 10.1377/hlthaff.23.5.210
© 2004 by Project HOPE
 
New Online
 * McAllen, TX & Beyond: An Expert Roundtable
 * Geography & Reform
 * Medicaid or Insurance Exchange?
 * Siren Song of New GME
 * Public Plan Option: Pro & Con
This Article
* Figures Only
* Full Text (HTML)
* Reprint (PDF)
* Submit a response to this article
* Alert me when this article is cited
* Alert me when Comments are posted
* Alert me if a correction is posted
Services
* E-mail this article to a friend
* Similar articles in this journal
* Similar articles in ISI Web of Science
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Personal Archive
* Download to Citation Manager
*Reprints & Permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via ISI Web of Science (5)
* Citing Articles via Google Scholar
Google Scholar
* Articles by Druss, B. G.
* Articles by Pincus, H. A.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Druss, B. G.
* Articles by Pincus, H. A.
Related Collections
* Legal/Regulatory Issues
* Business Of Health
* Pharmaceuticals
* Chronic Care
* Health Spending

Health Tracking

MARKETWATCH

Listening To Generic Prozac: Winners, Losers, And Sideliners

Benjamin G. Druss, Steven C. Marcus, Mark Olfson and Harold Alan Pincus

This study tracks the diffusion of generic fluoxetine after its release in August 2001 within the largest U.S. pharmacy benefit manager (PBM). Within two weeks of the generic’s release, prescriptions exceeded those of brand-name Prozac. The main winners proved to be Barr Laboratories, the first entrant to the generic market; large purchasers, who reaped substantial cost savings after Barr’s period of exclusivity expired; and the PBM. The major loser was Eli Lilly, the manufacturer of Prozac. Consumers and makers of other antidepressants largely remained on the sidelines, with surprisingly little short-term impact evident from Prozac’s patent expiration.


Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati    What's this?


This article has been cited by other articles:


Home page
Health Aff (Millwood)Home page
J. Donohue
Mental health in the medicare part d drug benefit: a new regulatory model?
Health Aff., May 1, 2006; 25(3): 707 - 719.
[Abstract] [Full Text] [PDF]



Home | Current Issue | Archives | Topic Collections | Search | Blog | Subscribe | Contact Us | Help

© 2001-2004 Project HOPE–The People-to-People Organization
Terms and Policies